Symbols / PTIX
PTIX Chart
About
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 771.16K |
| Enterprise Value | 2.10M | Income | — | Sales | — |
| Book/sh | -2.43 | Cash/sh | 1.41 | Dividend Yield | — |
| Payout | 0.00% | Employees | 1 | IPO | — |
| P/E | — | Forward P/E | -0.69 | PEG | — |
| P/S | — | P/B | -0.16 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -13.13 | EPS next Y | -0.58 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2022-04-07 17:00 | ROA | — |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.93M |
| Shs Float | — | Short Float | 3.32% | Short Ratio | 0.56 |
| Short Interest | — | 52W High | 14.28 | 52W Low | 0.25 |
| Beta | — | Avg Volume | 94.18K | Volume | 5.00K |
| Target Price | — | Recom | None | Prev Close | $0.45 |
| Price | $0.40 | Change | -11.11% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.40
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
Current target
$0.40
Low
—
High
—
Mean
—
- Protagenic Therapeutics Inc (stock code: PTIX) recently disclosed in a filing to the U.S. Securities and Exchange Commission (SEC) that the company officially signed a settlement agreement with former Phytanix shareholders on February 17. - Bitget ue, 24 Feb 2026 11
- Protagenic Therapeutics Unwinds Phytanix Deal and Settles Litigation - TipRanks ue, 24 Feb 2026 11
- Biotech Protagenic Therapeutics Working to Maintain Nasdaq Compliance After Merger-Related Filing Delay - Stock Titan Fri, 22 Aug 2025 07
- Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice - Livingston Daily hu, 27 Nov 2025 08
- Protagenic Therapeutics Received Notice of Delisting - TradingView Mon, 05 Jan 2026 08
- Will PTIX stock outperform international peers - Short Setup & Advanced Swing Trade Entry Plans - mfd.ru Fri, 13 Feb 2026 05
- Protagenic Therapeutics stock rises after completing Phase 1 dosing - Investing.com hu, 13 Nov 2025 08
- Novel Brain Hormone Therapy PT00114 Targets Stress Response: Protagenic's Phase 1 Trial Advances - Stock Titan hu, 21 Aug 2025 07
- Protagenic & Phytanix Merge in All-Stock Move, Sparking Retail Frenzy - Yahoo Finance hu, 29 May 2025 07
- Growth or Bubble? Decoding the Rapid Rise of PTIX - StocksToTrade Mon, 19 May 2025 07
- Protagenic Therapeutics Stock Leaps: A Moment to Ponder? - timothysykes.com hu, 21 Aug 2025 07
- Protagenic Therapeutics announces delay in quarterly filing - TipRanks Wed, 18 Feb 2026 12
- Protagenic Therapeutics files complaint in Delaware seeking rescission of Phytanix Bio acquisition - Investing.com Fri, 31 Oct 2025 07
- PTIX Faces Market Tremors: Analyzing the Shifts - StocksToTrade hu, 21 Aug 2025 07
- PTIX Stock Price, News & Analysis - Stock Titan Fri, 25 Apr 2025 02
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -5.53M | -4.23M | -3.37M | -4.11M |
| TotalUnusualItems | 51.73K | -630.32K | -46.05K | 81.18K |
| TotalUnusualItemsExcludingGoodwill | 51.73K | -630.32K | -46.05K | 81.18K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -5.53M | -5.00M | -3.56M | -4.52M |
| ReconciledDepreciation | 50.29K | 28.22K | 30.00 | 0.00 |
| EBITDA | -5.48M | -4.86M | -3.42M | -4.03M |
| EBIT | -5.53M | -4.89M | -3.42M | -4.03M |
| NetInterestIncome | 43.47K | 156.79K | 48.33K | -463.70K |
| InterestExpense | 0.00 | 107.68K | 137.46K | 496.91K |
| InterestIncome | 43.47K | 264.48K | 185.79K | 33.21K |
| NormalizedIncome | -5.58M | -4.37M | -3.51M | -4.60M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -5.53M | -5.00M | -3.56M | -4.52M |
| TotalExpenses | 5.70M | 4.53M | 3.56M | 4.14M |
| TotalOperatingIncomeAsReported | -5.70M | -4.53M | -3.56M | -4.14M |
| DilutedAverageShares | 350.00K | 310.33K | 308.42K | 263.23K |
| BasicAverageShares | 350.00K | 310.33K | 308.42K | 263.23K |
| DilutedEPS | -15.82 | -16.10 | -11.48 | -17.36 |
| BasicEPS | -15.82 | -16.10 | -11.48 | -17.36 |
| DilutedNIAvailtoComStockholders | -5.53M | -5.00M | -3.56M | -4.52M |
| NetIncomeCommonStockholders | -5.53M | -5.00M | -3.56M | -4.52M |
| NetIncome | -5.53M | -5.00M | -3.56M | -4.52M |
| NetIncomeIncludingNoncontrollingInterests | -5.53M | -5.00M | -3.56M | -4.52M |
| NetIncomeContinuousOperations | -5.53M | -5.00M | -3.56M | -4.52M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -5.53M | -5.00M | -3.56M | -4.52M |
| OtherIncomeExpense | 132.14K | -630.32K | -46.05K | 81.18K |
| OtherNonOperatingIncomeExpenses | 80.41K | |||
| GainOnSaleOfSecurity | 51.73K | -630.32K | -46.05K | 81.18K |
| NetNonOperatingInterestIncomeExpense | 43.47K | 156.79K | 48.33K | -463.70K |
| InterestExpenseNonOperating | 0.00 | 107.68K | 137.46K | 496.91K |
| InterestIncomeNonOperating | 43.47K | 264.48K | 185.79K | 33.21K |
| OperatingIncome | -5.70M | -4.53M | -3.56M | -4.14M |
| OperatingExpense | 5.70M | 4.53M | 3.56M | 4.14M |
| ResearchAndDevelopment | 3.94M | 3.32M | 1.59M | 1.14M |
| SellingGeneralAndAdministration | 1.76M | 1.21M | 1.97M | 3.00M |
| GeneralAndAdministrativeExpense | 1.76M | 1.21M | 1.97M | 3.00M |
| OtherGandA | 1.76M | 1.21M | 1.97M | 3.00M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 517.25K | 316.80K | 308.67K | 307.31K |
| ShareIssued | 517.25K | 316.80K | 308.67K | 307.31K |
| NetDebt | 129.04K | |||
| TotalDebt | 344.23K | 318.43K | ||
| TangibleBookValue | 1.01M | 3.67M | 6.92M | 9.94M |
| InvestedCapital | 1.01M | 3.67M | 7.26M | 10.26M |
| WorkingCapital | 940.11K | 3.54M | 6.92M | 10.26M |
| NetTangibleAssets | 1.01M | 3.67M | 6.92M | 9.94M |
| CommonStockEquity | 1.01M | 3.67M | 6.92M | 9.94M |
| TotalCapitalization | 1.01M | 3.67M | 6.92M | 10.26M |
| TotalEquityGrossMinorityInterest | 1.01M | 3.67M | 6.92M | 9.94M |
| StockholdersEquity | 1.01M | 3.67M | 6.92M | 9.94M |
| GainsLossesNotAffectingRetainedEarnings | -129.85K | -113.55K | -676.91K | -248.35K |
| OtherEquityAdjustments | -129.85K | -113.55K | -676.91K | -248.35K |
| RetainedEarnings | -36.30M | -30.78M | -25.78M | -22.22M |
| AdditionalPaidInCapital | 37.45M | 34.56M | 33.37M | 32.41M |
| CapitalStock | 725.00 | 444.00 | 434.00 | 432.00 |
| CommonStock | 725.00 | 444.00 | 434.00 | 432.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 942.76K | 655.25K | 1.12M | 1.12M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 318.43K |
| LongTermDebtAndCapitalLeaseObligation | 318.43K | |||
| LongTermDebt | 318.43K | |||
| CurrentLiabilities | 942.76K | 655.25K | 1.12M | 799.53K |
| OtherCurrentLiabilities | 10.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 344.23K | |||
| CurrentDebt | 344.23K | |||
| OtherCurrentBorrowings | 344.23K | |||
| PayablesAndAccruedExpenses | 942.76K | 655.25K | 775.63K | 799.53K |
| CurrentAccruedExpenses | 839.80K | 541.45K | 620.15K | 520.58K |
| Payables | 102.96K | 113.80K | 155.49K | 278.96K |
| AccountsPayable | 102.96K | 113.80K | 155.49K | 278.96K |
| TotalAssets | 1.96M | 4.32M | 8.04M | 11.06M |
| TotalNonCurrentAssets | 73.05K | 123.33K | 1.77K | 0.00 |
| NetPPE | 73.05K | 123.33K | 1.77K | 0.00 |
| CurrentAssets | 1.88M | 4.20M | 8.04M | 11.06M |
| PrepaidAssets | 44.40K | 144.03K | 56.94K | 688.67K |
| CashCashEquivalentsAndShortTermInvestments | 1.84M | 4.06M | 7.98M | 10.37M |
| OtherShortTermInvestments | 0.00 | 2.77M | 7.76M | 9.83M |
| CashAndCashEquivalents | 1.84M | 1.29M | 215.19K | 541.17K |
| CashFinancial | 1.84M | 1.29M | 215.19K | 541.17K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -4.22M | -3.85M | -2.00M | -2.80M |
| RepaymentOfDebt | 0.00 | -100.00K | ||
| IssuanceOfDebt | 0.00 | 100.00K | ||
| IssuanceOfCapitalStock | 1.96M | 0.00 | 0.00 | 11.71M |
| CapitalExpenditure | -149.78K | -1.80K | ||
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 1.84M | 1.29M | 215.19K | 541.17K |
| BeginningCashPosition | 1.29M | 215.19K | 541.17K | 671.09K |
| EffectOfExchangeRateChanges | 667.00 | 998.00 | 70.86K | 631.00 |
| ChangesInCash | 549.91K | 1.07M | -396.84K | -130.55K |
| FinancingCashFlow | 1.96M | 0.00 | 0.00 | 12.58M |
| CashFlowFromContinuingFinancingActivities | 1.96M | 0.00 | 0.00 | 12.58M |
| NetOtherFinancingCharges | 11.71M | |||
| ProceedsFromStockOptionExercised | 0.00 | 869.62K | ||
| NetCommonStockIssuance | 1.96M | 0.00 | 0.00 | 11.71M |
| CommonStockIssuance | 1.96M | 0.00 | 0.00 | 11.71M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | ||
| NetShortTermDebtIssuance | 0.00 | 100.00K | ||
| ShortTermDebtIssuance | 0.00 | 100.00K | ||
| NetLongTermDebtIssuance | 0.00 | -100.00K | ||
| LongTermDebtPayments | 0.00 | -100.00K | ||
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | 2.80M | 4.78M | 1.60M | -9.91M |
| CashFlowFromContinuingInvestingActivities | 2.80M | 4.78M | 1.60M | -9.91M |
| NetInvestmentPurchaseAndSale | 2.80M | 4.93M | 1.60M | -9.91M |
| SaleOfInvestment | 3.10M | 7.69M | 1.63M | 485.95K |
| PurchaseOfInvestment | -297.12K | -2.76M | -34.12K | -10.40M |
| NetPPEPurchaseAndSale | 0.00 | -149.78K | -1.80K | 0.00 |
| PurchaseOfPPE | 0.00 | -149.78K | -1.80K | 0.00 |
| OperatingCashFlow | -4.22M | -3.70M | -1.99M | -2.80M |
| CashFlowFromContinuingOperatingActivities | -4.22M | -3.70M | -1.99M | -2.80M |
| ChangeInWorkingCapital | 467.54K | -114.41K | 540.13K | -140.39K |
| ChangeInPayablesAndAccruedExpense | 367.92K | -27.33K | -91.60K | 340.12K |
| ChangeInPrepaidAssets | 99.63K | -87.09K | 631.73K | -480.51K |
| OtherNonCashItems | -80.41K | 85.77K | 110.80K | 427.14K |
| StockBasedCompensation | 923.14K | 666.83K | 864.68K | 1.52M |
| DepreciationAmortizationDepletion | 50.29K | 28.22K | 30.00 | 0.00 |
| DepreciationAndAmortization | 50.29K | 28.22K | 30.00 | 0.00 |
| Depreciation | 50.29K | 28.22K | 30.00 | 0.00 |
| OperatingGainsLosses | -51.73K | 630.32K | 46.05K | -81.18K |
| GainLossOnInvestmentSecurities | -51.73K | 630.32K | 46.05K | -81.18K |
| NetIncomeFromContinuingOperations | -5.53M | -5.00M | -3.56M | -4.52M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PTIX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|